公开(公告)号：US20230340529A1

公开(公告)日：2023-10-26

申请号：US18024359

申请日：2021-09-02

Applicant: University of Massachusetts

Inventor： Guangping Gao ,  Philip Tai ,  Claudio Punzo ,  Haijiang Lin

IPC: C12N15/86 ,  A61K35/761

CPC classification number: C12N15/86 ,  A61K35/761 ,  C12N2750/14143 ,  C12N2750/14171 ,  C12N2750/14122

Abstract: Aspects of the disclosure relate to compositions and methods for expressing anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the disclosure provides rAAVs comprising a capsid protein (e.g., AAV2 variants, AAV2/3 hybrid variants, AAV8 variants, etc.), and a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.

公开(公告)号：US20230048017A1

公开(公告)日：2023-02-16

申请号：US17685457

申请日：2022-03-03

Applicant: University of Massachusetts

Inventor： Guangping Gao ,  Phillip Tai ,  Claudio Punzo ,  Haijiang Lin

IPC: C12N15/86 ,  C07K14/005 ,  C12N7/00 ,  A61K35/76 ,  A61P9/00

Abstract: Aspects of the disclosure relate to compositions and methods for expressing anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the disclosure provides rAAVs comprising a capsid protein (e.g., AAV2 variants, AAV2/3 hybrid variants, AAV8 variants, etc.), and a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.